Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer

December 04, 2008

Cincinnati Children's study shows possible new cancer risk and path to testing treatments

CINCINNATI - A genetic malfunction that causes DNA instability in people with the blood disorder Fanconi anemia may put them at high risk for squamous cell carcinomas linked to human papillomavirus (HPV), according to a study posted online ahead of print by Oncogene.

Researchers led by Cincinnati Children's Hospital Medical Center report the breakdown of a cell signaling pathway for the FA (Fanconi Anemia) gene complex triggers cellular abnormalities, when then are made worse by HPV cancer genes in skin cells. This opens the door to a high risk of developing squamous cell carcinoma solid tumors, which develop from skin cells, according to the investigators.

Restoring the FA pathway reverses irregular cell growth in HPV positive cells and may reduce cancer risk, the study suggests. FA restoration also may be a potential candidate for therapy, although the researchers cautioned more research is needed before linking the findings to clinical situations.

"We are suggesting that restoring the FA pathway to treat Fanconi anemia-related cancer might be a worthwhile clinical endeavor," said Susanne Wells, Ph.D., a researcher in the division of Hematology/Oncology at Cincinnati Children's and the study's senior investigator. "This study is the first time we've been able to investigate a link between Fanconi anemia-associated cancers and HPV in cells very closely resembling living human skin, adding to the significance of this research."

Fanconi anemia is a rare, inherited genetic instability syndrome that causes aplastic anemia and an often-fatal blood disorder. This leads to bone marrow failure, organ damage and increased susceptibility to cancer. The disorder typically develops in early childhood and the average life span for people with Fanconi anemia is 20 to 30 years.

Although a bone marrow transplant can cure the blood disorder, people with Fanconi anemia remain at risk for solid tumors. The most common is squamous cell carcinoma of the head, neck, skin or anogenital region. Current treatments for these cancers are limited mainly to surgery or radiation, which is less than ideal because of underlying DNA instability in Fanconi anemia patients. The current study is part of a larger effort to find more effective and safer treatments, said Dr. Wells, also associate professor of pediatrics at the University of Cincinnati College of Medicine.

The FA gene complex and pathway are known to play an important role in DNA repair. According to this study, which used skin cells from Fanconi anemia patients, FA also helps maintain proper functioning of the cell cycle - specifically a cell's exit from the duplication of genetic material prior to division.

The current study examined Fanconi anemia-related squamous cell carcinoma with HPV because some research suggests a connection, although molecularly it remains unproven. One reason is the molecular changes that lead to cancer in FA-deficient keratinocytes (the skin cell of origin for squamous cell carcinoma) are poorly understood. This study, which uses keratinocytes, begins to help explain some of these changes.

Together with physicians in the Fanconi Anemia Comprehensive Care Center at Cincinnati Children's, Dr. Wells' team collected keratinocytes from patients. They analyzed the cells in a laboratory cell culture system that recreates the biology of normal epithelial tissue, or skin. Fanconi Anemia patients can be deficient in one of 13 distinct genes, all working in the same pathway. Most patients have what is called the FANCA complementation group, with mutations in the FANCA gene.

The HPV cancer genes E6/E7 were artificially introduced to FANCA-patient skin cells and grown in the three-dimensional organotypic raft culture that simulates skin. The investigators observed irregular cell growth and increased skin thickness in the culture. Restoring FANCA gene function in the skin reduced irregular cell growth and skin thickness. In a reverse experiment, the researchers took FA-normal cells, where the FA gene pathway is not broken. The FA-normal cells also carried the HPV cancer genes E6/E7. The investigators then switched off two Fanconi anemia genes in the cells (FANCA and FANCD2). This disabled the FA pathway and resulted in irregular cell growth and thickening of epithelial/skin tissue.

The HPV E6/E7 genes are known to inhibit natural tumor suppression and promote chromosomal instability in the cell replication cycle. Dr. Wells and her colleagues believe FA deficiency may accelerate tumor development by promoting genomic instability, which then cooperates with HPV's inactivation of the body's natural tumor suppressors. Restoring the FA gene pathway, they suggest, can block cell cycle abnormalities stimulated by high-risk HPV E6/E7.

The researchers also experimented with standard cell cultures that aren't as close to mimicking living skin. In those experiments, cellular abnormalities did not occur until the researchers introduced DNA damaging agents, such as the chemotherapy agent mitomycin C. After exposure the cells experienced programmed death. This may explain why skin lesions develop in some Fanconi anemia patients who have residual DNA damage following certain treatments. Dr. Wells said it's also possible residual DNA damage mutates surviving cells, which can cause cancer. The results show how sensitive FANCA-deficient skin cells are to DNA damage from external sources, highlighting in part the vulnerability Fanconi anemia patients can have to certain forms of cancer treatment.

The study's results also have potential implications for cancers not linked to Fanconi anemia. Previous research has shown inactivation of the FA pathway has been detected in some cancers affecting people without the blood disorder. The skin cell model researchers developed for the current study could be used to advance research of FA-deficient squamous cell carcinomas in the general population, they report.

Coming up next for the multi-institutional research team is trying to grow FA/HPV associated tumors in mice to see if restoration of the FANCA genetic pathway causes the cancer to shrink. Accomplishing this could lead to a preclinical model for testing novel approaches to cancer therapy, Dr. Wells said.

Cincinnati Children's Hospital Medical Center

---

---

	Basal and Squamous Cell Carcinomas: What every primary care physician should know (Postgraduate Medicine) by JTE Multimedia Skin cancer is a major threat to sun-loving Americans, afflicting about 20% of the general population at some point in life. The good news is detection is relatively simple, and screening can easily be incorporated into every physical examination. If basal or squamous cell cancers are found early, treatment is simple and usually successful. However, lifelong surveillance is extremely important in patients who have had skin cancer. Dr Marghoob discusses the characteristics of basal and squamous cell carcinomas and outlines diagnostic and therapeutic options. Original Publication Date: August 1997
	Metastatic cystic squamous cell carcinoma.(PATHOLOGY CLINIC): An article from: Ear, Nose and Throat Journal by Lester D.R. Thompson (Author) This digital document is an article from Ear, Nose and Throat Journal, published by Thomson Gale on May 1, 2005. The length of the article is 527 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Metastatic cystic squamous cell carcinoma.(PATHOLOGY CLINIC) Author: Lester D.R. Thompson Publication: Ear, Nose and Throat Journal (Magazine/Journal) Date: May 1, 2005 Publisher: Thomson Gale Volume: 84 Issue: 5 Page: 272(2) Distributed by Thomson...
	Treatment of Esophageal and Hypopharingeal Squamous Cell Carcinoma (Updates in Surgery) by Giovanni De Manzoni (Editor) Squamous cell carcinoma of the esophagus has a lower incidence than other gastrointestinal tract cancer; however, there are many difficult issued related to the choice of appropriate therapy for these patients. In recent years, the use of multimodal treatment has greatly improved the prognosis of patients affected by this disease but several aspects of the oncological and surgical management are still controversial. This book aims to give a homogeneous approach to esophageal cancer treatment, based on the author’s lifetime experience in conjunction with exhaustive review of recent literature. In each chapter surgeons and oncologists will find appropriate tools for correct management of the diagnosis and therapy of this difficult disease. The book analyzes all the aspects of staging and...
	Molecular Mechanisms of Basal Cell and Squamous Cell Carcinomas (Medical Intelligence Unit) by Jörg Reichrath (Editor) This book provides a comprehensive, highly readable overview of our current knowledge of the molecular pathology of basal cell and squamous cell carcinomas. The chapters present the newest findings in epidemiology, photocarcinogenesis, genetics, immunology and molecular pathology of these epithelial skin tumours. The book will interest researchers or clinicians interested in the carcinogenesis and biology of basal cell or squamous cell carcinomas.
	SCC antigen in the management of squamous cell carcinoma by Excerpta Medica (Publisher)
	Squamous Cell Carcinoma (Cancer Etiology, Diagnosis and Treatments) by Daniel V. Mortensen (Editor) Squamous cell carcinoma (SCC) is a form of cancer of the carcinoma type that may occur in many different organs, including the skin, lips, mouth, esophagus, urinary bladder, prostate, lungs, vagina and cervix. This new book presents topical research in the study of the ontogeny of squamous cell carcinoma with a focus on the regulation of cell proliferation in oral squamous cell carcinoma. Also discussed is squamous cell carcinoma arising in epidermal cysts and human papillomavirus associated cysts and oral cuniculatum carcinoma.
	QuickFACTS Basal and Squamous Cell Skin Cancer: What You Need to Know-NOW by American Cancer Society (Author) Complete with the most up-to-date patient treatment guidelines, this medical guide covers every aspect of basal and squamous cell skin cancer, from what the risk factors are to the benefits of early diagnosis to living healthily after treatment. Critical questions to ask the health care team are provided, as is an advanced dictionary of cancer-related terms. This pocket-sized reference aims to raise public awareness of skin cancer to promote early detection and emphasizes that all patients should be well-informed and play an active role in planning their own treatment.
	Squamous cell carcinoma of the skin: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed. by Anna, D.V.M., Ph.D. Spickler (Author), Rebecca, PhD Frey (Author) Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.
	Metastasis risk higher with prior SCC/BCC.(SKIN DISORDERS)(squamous cell carcinomas)(basal cell carcinomas)(Report): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on April 15, 2010. The length of the article is 371 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Metastasis risk higher with prior SCC/BCC.(SKIN DISORDERS)(squamous cell carcinomas)(basal cell carcinomas)(Report) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 15, 2010 Publisher: International Medical News Group Volume: 40 Issue: 7 Page: 25(1) Article Type: Report Distributed by Gale, a part of Cengage...
	21st Century Adult Cancer Sourcebook: Nonmelanoma Skin Cancer - Squamous Cell Carcinoma and Basal Cell Carcinoma (BCC and SCC) - Clinical Data for Patients, Families, and Physicians by Progressive Management Authoritative information and practical advice from the nation's cancer experts about nonmelanoma skin cancer includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references. Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of nonmelanoma skin cancer. Comprehensive data on clinical trials is included - with...